CLINICAL TRIALS PROFILE FOR VIZIMPRO
✉ Email this page to a colleague
All Clinical Trials for VIZIMPRO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03878524 ↗ | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | Recruiting | Oregon Health and Science University | Phase 1 | 2020-04-01 | This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy. |
| NCT03878524 ↗ | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | Recruiting | Prospect Creek Foundation | Phase 1 | 2020-04-01 | This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy. |
| NCT03878524 ↗ | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | Recruiting | OHSU Knight Cancer Institute | Phase 1 | 2020-04-01 | This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy. |
| NCT04027647 ↗ | Phase 2 Study of Dacomitinib in NSCLC | Recruiting | Pfizer | Phase 2 | 2019-09-11 | This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites. |
| NCT04027647 ↗ | Phase 2 Study of Dacomitinib in NSCLC | Recruiting | National Cancer Centre, Singapore | Phase 2 | 2019-09-11 | This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VIZIMPRO
Condition Name
| Condition Name for VIZIMPRO | |
| Intervention | Trials |
| Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | 1 |
| Recurrent Non-Hodgkin Lymphoma | 1 |
| Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis | 1 |
| Refractory Malignant Solid Neoplasm | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for VIZIMPRO
Trials by Country
Clinical Trial Progress for VIZIMPRO
Clinical Trial Phase
Clinical Trial Sponsors for VIZIMPRO
Sponsor Name
